BBS proteins interact genetically with the IFT pathway to influence SHH-related phenotypes

Qihong Zhang1, Seongjin Seo1, Kevin Bugge1, Edwin M. Stone2 and Val C. Sheffield1,∗

1Department of Pediatrics and 2Department of Ophthalmology and Visual Sciences, Howard Hughes Medical Institute, University of Iowa, 4181 MERF, Iowa City, IA 52242, USA

Received August 29, 2011; Revised November 18, 2011; Accepted January 4, 2012

There are numerous genes for which loss-of-function mutations do not produce apparent phenotypes even though statistically significant quantitative changes to biological pathways are observed. To evaluate the biological meaning of small effects is challenging. Bardet–Biedl syndrome (BBS) is a heterogeneous autosomal recessive disorder characterized by obesity, retinopathy, polydactyly, renal malformations, learning disabilities and hypogonitalism, as well as secondary phenotypes including diabetes and hypertension. BBS knockout mice recapitulate most human phenotypes including obesity, retinal degeneration and male infertility. However, BBS knockout mice do not develop polydactyly. Here we showed that the loss of BBS genes in mice result in accumulation of Smoothened and Patched 1 in cilia and have a decreased Shh response. Knockout of Bbs7 combined with a hypomorphic Ift88 allele (orpk as a model for Shh dysfunction) results in embryonic lethality with e12.5 embryos having exencephaly, pericardial edema, cleft palate and abnormal limb development, phenotypes not observed in Bbs7−/− mice. Our results indicate that BBS genes modulate Shh pathway activity and interact genetically with the intraflagellar transport (IFT) pathway to play a role in mammalian development. This study illustrates an effective approach to appreciate the biological significance of a small effect.

INTRODUCTION

The use of loss-of-function mutations is an informative approach to identify the functions of a given gene. Some loss-of-function mutations generate dramatic phenotypes in model systems, and these mutations have been pivotal to understanding biological pathways and molecular mechanisms for human diseases. However, numerous genes do not produce apparent phenotypes when knocked out, even though statistically significant quantitative changes to biological pathways are observed. To evaluate the biological meaning of these small effects is a scientific challenge.

Cilia are microtubule-based structures that extend from the cell surface of most cells and are classified as either motile or primary cilia (immotile). The importance of cilia is highlighted by defects in cilia that lead to the development of a wide range of human diseases termed ciliopathies, which include primary ciliary dyskinesis, polycystic kidney disease, nephronophthisis, Joubert syndrome, Senior–Loken syndrome, Meckel–Gruber syndrome, oro-facial-digital syndrome, Alstrom syndrome and Bardet–Biedl syndrome (BBS).

BBS (OMIM 209900) is an autosomal recessive genetic disorder characterized by obesity, retinopathy, polydactyly, renal malformations, learning disabilities and hypogonitalism, as well as diabetes and hypertension. To date, 16 BBS genes have been shown to independently cause the disorder (1–13). Seven BBS proteins (BBS1, BBS2, BBS4, BBS5, BBS7, BBS8 and BBS9) along with an interacting protein known as BBIP10 form a complex called the BBSome, which is involved in ciliary membrane biogenesis (14). Although several ciliary membrane proteins have been shown to require the BBSome for transport to cilia (15,16), the physiological relevance of some of these ciliary membrane proteins to BBS phenotypes are currently unknown.

BBS knockout mice display most human BBS phenotypes including obesity, retinal degeneration and male infertility. However, unlike human BBS patients, BBS knockout mice do not develop polydactyly (17–20). Most polydactyly phenotypes typically have the sonic hedgehog (Shh) pathway defects and the Shh pathway is known to control tissue patterning during mammalian development. Shh activates the pathway by binding to its receptor Patched 1 (Ptc1) releasing

∗To whom correspondence should be addressed. Tel: +1 3193356937; Fax: +1 3193357588; Email: val-sheffield@uiowa.edu

© The Author 2012. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Smoothened (Smo) from inhibition. Activated Smo transduces the signal via Gli transcription factors. There are three Gli proteins (Gli1, Gli2 and Gli3) in vertebrates. Gli2 and Gli3 are the primary regulators of the pathway during development (21).

It is well established that cilia are required for hedgehog pathway signaling (22–27). BBS mutant mice have motile cilia defects in brain ependymal cells, trachea epithelial cells and sperm flagella, but they do not have apparent primary cilia morphological defects, although the primary cilium may have functional deficits (17–20). While the loss of BBS function has been shown to result in wingless-type MMTV integration site (Wnt)/planar cell polarity defects (28–31), it is not clear whether the loss of BBS genes also affect the Shh pathway. The lack of the polydactyly phenotype in BBS mutant mice prompted us to investigate the underlying molecular defects in BBS mutant mice. Here we showed that Smo and Ptch1 are endogenous cargos of the BBSome and that the loss of BBS genes in mice results in accumulation of Smo and Ptch1 in cilia and lead to a quantitative decrease in Shh response.

RESULTS

The BBSome regulates Smo ciliary localization and Shh signaling

One of the cardinal features of BBS is post-axial polydactyly, which is present in most human BBS patients. However, none of the BBS mutant mice (Bbs1<sup>M390R/M390R</sup>, Bbs2<sup>−/−</sup>, Bbs4<sup>−/−</sup>, Bbs6<sup>−/−</sup> and Bbs7<sup>−/−</sup>) develop polydactyly (17–20). Most mutant mice that have polydactyly have defective Shh signaling; therefore, we examined the Shh pathway in BBS mutant mice. We isolated mouse embryonic fibroblast (MEF) cells and embryonic brain cells from wild-type (WT) and Bbs mutant mice (Bbs1<sup>M390R/M390R</sup> knockin, Bbs2<sup>−/−</sup>, Bbs4<sup>−/−</sup>, Bbs6<sup>−/−</sup> and Bbs7<sup>−/−</sup>). MEF and embryonic brain cells are known to respond to hedgehog ligand stimulation (32). Smo, one of the hedgehog pathway components, localizes to cilia when stimulated by Shh ligand or by pathway agonists such as N-Methyl-N′-(3-pyridinylbenzyl)-N′-(3-chlorobenzoyl)[b]thiophene-2-carbonyl]-1,4-diaminocyclohexane (SAG). To determine whether the loss of the BBSome affects Smo ciliary localization, we stimulated cultured WT and Bbs7<sup>−/−</sup> MEF cells with the Shh pathway agonist SAG. About 45% of cilia are Smo positive in BBS mutant MEF cells even without stimulation with SAG (Fig. 1A and C) compared

Figure 1. The BBSome regulates Smo ciliary localization and Shh signaling. (A) Cultured MEF cells from WT and Bbs7<sup>−/−</sup> mice stimulated with dimethyl sulfoxide (DMSO) or with Shh pathway activator N-Methyl-N′-(3-pyridinylbenzyl)-N′-(3-chlorobenzoyl)[b]thiophene-2-carbonyl]-1,4-diaminocyclohexane (SAG) were stained with anti-acetylated tubulin (green) as a cilia marker and anti-Smo (red). (B) Quantitation of percentage of cells with cilia with or without SAG treatment found no differences between WT and Bbs7<sup>−/−</sup> MEF cells. (C) Quantitation of percentage of cilia with Smo staining when treated with DMSO or SAG. (D) qPCR for Gli1 and Patched 1 from cultured Bbs7<sup>−/−</sup> MEF cells stimulated with SAG showed a 20–30% decreased Shh pathway output compared with WT MEF cells when normalized to actin. Scale bar represents 10 μm. *P < 0.02.
with <5% of WT MEF cells having Smo staining. SAG stimulation increases the percentage of cilia that are Smo positive to nearly 100% in both WT and Bbs7^{−/−} cells (Fig. 1A and C). Similar results were obtained with cultured brain cells (data not shown). These data indicate that the loss of BBS increases the basal level of Smo in cilia, perhaps by affecting Smo retrograde transport out of cilia, since BBS genes have been shown to be required for retrograde transport in model systems including zebrafish and Chlamydomonas reinhardtii (33,34). Similar results are obtained using MEF cells from Bbs1^{M390R/M390R} knockin, Bbs2^{−/−} and Bbs4^{−/−} (data not shown). To determine whether the increased ciliary localization of Smo in the absence of normal BBS genes results in a 20–30% decrease in Shh pathway activation in MEF cells (Fig. 1D). These results are consistent with the notion that ciliary localization Smo has two states: inactive and active. Ciliary localization of Smo is not sufficient to activate the pathway (25). The BBSome may modulate the conversion of Smo from the inactive to the active state within cilia.

The BBSome interacts with Smo

To further analyze how the loss of the BBSome affects ciliary localization of Smo, we examined whether the BBSome interacts physically with Smo. This was performed by co-transfection of each individually hemagglutinin (HA)-tagged BBSome component (BBS1, 2, 4, 5, 7, 8 and 9) with either GFP- or Flag-tagged Smo. Using a reciprocal immunoprecipitation assay, we demonstrated that full-length Smo interacts with several BBSome subunits with BBS1 showing the strongest interaction (Fig. 2A and Supplementary Material, Fig. S1D). BBS1 specifically binds to the C-terminal cytoplasmic tail of Smo (amino acids 477–793) (Fig. 2B). It has been previously demonstrated that the minimal region of Smo that is required for activity comprises amino acids 1–637 (35). We demonstrated with deletion analysis that BBS1 binds to the C-terminal region that contains a stretch of only 10 basic amino acids. (C) Domain-binding analysis reveals that BBS1 binds to the Smo C-terminal region between amino acid 552–637. (D and E) A stretch of 10 basic amino acids in the Smo C-terminal tail regulates the interaction between Smo and BBS1.

Studies from Drosophila show that hedgehog induces phosphorylation of multiple Ser/Thr residues to antagonize multiple Arg clusters in the Smo C-terminal cytoplasmic tail to induce an Smo conformational change and activate the pathway (36). Vertebrate Smo also contains two clusters of basic amino acids in the cytoplasmic tail (Fig. 2E), and Shh induces a conformational change (36). We asked whether this conformational switch regulates the interaction with the BBSome. Deletion of a stretch of 10 basic amino acids in the Smo C-terminal tail enhances its interaction with BBS1 (Fig. 2D), whereas deleting a stretch of 17 basic amino acids has minimal effect on the interaction with BBS1. None of these deletion mutations affects the ciliary localization of Smo (Supplementary Material, Fig. S1).

The BBSome regulates Ptch1 ciliary localization

Ptch1, another membrane protein of the hedgehog pathway, is a hedgehog receptor and localizes to the cilia. To determine...
whether the BBSome also regulates Ptc1 ciliary localization, we stained MEF cells from WT and Bbs72/2 mice with anti-
body against Ptc1. Increased Ptc1 staining was detected in
the cilia of Bbs72/2 MEF cells compared with WT MEF
cells when stimulated with SAG (Fig. 3A and B). Similar
results are obtained using MEF cells from Bbs1M390R/M390R
knockin, Bbs22/2 and Bbs42/2 (data not shown). This result
may explain the deceased Shh response in BBS knockout
cells as Ptc1 is a negative regulator of the Shh pathway.

To further analyze how the loss of BBSome affects Ptc1
ciliary localization, we tested whether the BBSome directly
interacts with Ptc1. Co-transfection of Flag-tagged C-terminal cytoplasmic tail of Ptc1 along with HA-tagged in-
dividual BBSome subunits (BBS1, 2, 4, 5, 7, 8 and 9) revealed
that the C-terminal tail of Ptc1 interacts strongly with BBS1
(Fig. 3C), while no interaction or very weak interaction was
detected with other BBSome subunits. Structure analysis using
SMART does not reveal any domains analogous to any
known proteins in the C-terminal tail of Ptc1 and only four
low-complexity regions are found. We therefore chose to
make deletions that separate these four low-complexity
regions and showed that amino acids 1322–1447 of the
C-terminus of Ptc1 are required for binding to BBS1 (Fig. 3D).

Genetic interaction between Bbs7 and Ift88 affects
mammalian development

Although BBS knockout mice do not develop polydactyly, our in vitro studies indicate statistically significant differences in
the Shh pathway activation in response to Shh agonist, suggest-
ing that the loss of BBS proteins may sensitize mice to
hedgehog pathway defects. We reasoned that further reduction
in the Shh response in BBS mutant mice would result in
polydactyly. Ift88 hypomorphic ORPK mice have greatly
decreased Ift88 protein levels, improper IFT complex B for-
mation, hedgehog signaling defects and polydactyly (Supple-
mentary Material, Fig. S5). Interestingly, ORPK MEF cells
also accumulate Smo in the cilia even without SAG stimu-
lation (Supplementary Material, Fig. S5C), consistent with
the finding that polycystin-2 is accumulated inside the
cilium in ORPK mice (37). The BBSome interacts with IFT
proteins when expressed in cells and co-localizes at punctae
inside the cilium (Supplementary Material, Fig. S6), although
the endogenous protein interaction cannot be detected (Sup-
plementary Material, Fig. S5B). In ORPK mice, polydactyly
is only displayed in the hindlimb (38). Although ORPK
mice have multiple organ defects including cystic kidneys,
hydrocephalus, liver fibrosis, pancreatitis and retinal degener-
ation (39–41), they survive to adulthood on a C57BL/6 back-
ground and otherwise appear to be normal. It has been shown
that knocking down any BBSome subunit in cell culture
resulted in the loss of BBSome formation (42). We have con-
firmed that there is no BBSome formation in the absence of
Bbs7 (data not shown). Therefore, we use Bbs7+/− as a surro-
gate for the loss of the BBSome. When we crossed Bbs7+/−; orpk+/− double heterozygotes with each other. No double
mutant offspring were found at weaning out of 145 offspring,
suggesting that they may die prenatally or perinatally. We
therefore closely followed the mice at birth and genotyped
99 P0 offspring. No double mutants were found, indicating
prenatal death. Timed matings were set up and fetuses were

Figure 3. The BBSome regulates Ptc1 ciliary localization. (A) Cultured MEF cells from WT and Bbs7−/− mice stimulated with the Shh pathway activator,
SAG, were stained with anti-acetylated tubulin (green) as a cilia marker and anti-Ptc1 (red). (B) Quantitation of the intensity of Ptc1 staining inside cilia when
treated with SAG. Bbs7−/− MEF cells have statistically higher amount of Ptc1 inside the cilia compared with WT MEF cells. (C) Shown are reciprocal immu-
noprecipitation assays in 293T cells of HA-tagged each BBSome components with Flag-tagged Ptc1. Ptc1 interacts with the BBSome through the BBS1
subunit. (D) BBS1 interacts with the C-terminal tail of Ptc1 between amino acid 1322–1447. Scale bar represents 10 μm.
double mutants (6.25% predicted based on Mendelian ratios at two independent loci). Double-mutant embryos have exencephaly, pericardial edema, no eye development and cleft palate (Fig. 4). Neither the homozygous single mutants, nor homozygous single mutant animals that were heterozygous at the other locus had phenotypes similar to the double homozygous mutant mice. Limb development of the double mutant embryos is delayed in that e11.5 limbs morphologically look like e10.5 WT limbs and e12.5 limbs morphologically look like e11.5 WT limbs and lack calcification. In addition to the delayed morphological appearance, the e12.5 limb buds of the double-mutant embryos are broad compared with e11.5 WT limb buds, suggesting polydactyly (Fig. 4D). Double mutants do not survive beyond e12.5, which precluded us from identifying the exact digit numbers. These findings indicate that double mutants have severe Shh pathway defects and resemble complete knockout of IFT genes. Indeed, MEF cells from Bbs7 and Ift88orpk double mutant have further decreased the Shh response by RT–PCR assay of Gli1 expression level compared with Ift88orpk single mutant when treated with SAG (E), we diluted WT cDNA by 10-fold in order to see Gli1 band in double mutant.

DISCUSSION

The importance of cilia is highlighted by the fact that numerous diseases have been associated with defects in cilia structure or cilia function. It is well established that cilia are required for the hedgehog pathway (23–26,43,44). Involvement of cilia in Wnt/β-catenin and Wnt/PCP signaling pathways are more controversial (45–47), although accumulating evidence supports that cilia are also important for these pathways (30,48–51). It has been reported that BBS knockout mice develop phenotypes similar to Wnt/PCP pathway mutants including midbrain exencephaly and open eyelids (30). However, we have not detected such defects in any of the BBS mutant mice (Bbs1M390R/M390R knockin, Bbs2−/−, Bbs4−−, Bbs6−− and Bbs7−−) either on 129Sv, C57BL6 or mixed genetic backgrounds (our unpublished data). We also recover mendelian ratios of embryos at e12.5. One possible explanation for the discrepancy between our mice and other reported mouse models is that BBS mutant mice generated in our laboratory were generated using homologous recombination, while BBS mutant mice that showed PCP defects were generated by gene-trapping methodology. The accumulation of endogenous Smo in cilia implies that transport of Smo out of cilia is dependent on BBSome function. This result is reminiscent of the localization of Smo in Dyn2h1 mutant MEFs (46,52). In Dyn2h1 mutant MEFs,
Smo is constitutively present in cilia but the presence of Smo is not sufficient to activate the hedgehog pathway. While stimulation of Dyn2h1 MEF cells with SAG does not increase Smo ciliary localization, stimulation of BBS mutant MEF cells with SAG further increases Smo ciliary localization, indicating that BBS mutant MEF cells can respond to Shh pathway activation, although the response is diminished. This difference could explain why Dyn2h1 mutant mice have developmental defects including polydactyly, while BBS mutant mice do not. Consistent with the results from mouse studies, skin fibroblast cells derived from the most common human BBS mutation: BBS1M390R also accumulate Smo in the cilia even without SAG stimulation (Supplementary Material, Fig. S8), indicating that the underlying mechanism is conserved between mouse and humans.

The accumulation of both Smo and Ptch1 in BBS null MEF cells is consistent with genetic studies in zebrafish in which knockdown of Bbs gene expression results in the delay of melanosome retrograde transport (34), which is mediated by the dynein complex. In an attempt to identify potential binding partners for BBS proteins, we performed yeast 2-hybrid screens using BBS proteins as baits. Interestingly, cytoplasmic dynein light intermediate chain 1 and p150glued interact with BBS proteins. These interactions were confirmed in vivo using co-immunoprecipitation assays (Supplementary Material, Fig. S3). Considering that the BBSome has been suggested as a cargo for the IFT complex, and reportedly serves as a bridge between IFT complex A and IFT complex B in C. elegans (33,53), it was somewhat surprising to us that no IFT proteins were identified in our Y2H screen. One explanation is that the interaction requires the intact BBSome and the intact IFT complex, not individual components. The cargo—BBSome—dynein complex link could be an underlying molecular mechanism involved in BBS phenotypes. How the loss of BBS affects the cargo—dynein complex interaction will be the focus of future work.

Several possibilities can explain why increased ciliary localization of Smo did not result in increased Shh pathway activation. First, Smo localized within cilia has two states: inactivated and activated (25). The BBSome may be required to modulate the conversion from the inactive to the active state inside the cilium. Second, Ptch1, a negative regulator of the hedgehog pathway, normally moves out of cilia when the pathway is activated. However, accumulation of Ptch1 within cilia in the absence of BBS components may inhibit Shh pathway activation. Recent studies have shown that Shh ligand transmits the signal through regulating Gli-Su(fu) ciliary entry and subsequent dissociation of Gli and Su(fu) leading to the activation of Gli transcription factors and activation of the pathway (54–56). Although the BBSome can interact with Gli1, Gli2 and Su(fu) (Supplementary Material, Fig. S4), unlike Dyn2h1 MEF cells, BBS mutant MEF cells do not accumulate Gli2 inside cilia (Supplementary Material, Fig. S7), suggesting that the BBSome may transport specific ciliary membrane proteins.

In Drosophila, the atypical kinesin Costal-2 serves as an adaptor between transmembrane transducer Smo and the transcriptional effector Cubitus interruptus (57). The mammalian homolog of Costal-2 is kif7. Whether kif7 has a similar role as Costal-2 to bridge Smo to Gli proteins is currently unknown. Physical interactions between the BBSome, Smo C-terminus and Gli-Su(fu) suggests that the BBSome may play a role in this process. Attempts to detect the physical interactions among the endogenous BBSome, Smo and Gli-Su(fu) were unsuccessful. This is not surprising, considering that the BBSome is a part of a transport system, and we thus expect that the interactions between the BBSome and its cargoes [Smo, Ptch1 and Gli-Su(fu) or other hedgehog pathway components] will be transient and weak due to the need to constantly load and release cargoes. One illustrative example is that IFT complexes are known to require both the antegrade motor, kinesin II and the retrograde motor, dynein, to power the movement of IFT particles. No endogenous interactions between IFT complexes and motors have been detected. Another example is that the BBSome and IFT complexes co-localize inside Chlamydomonas flagella and the BBSome appears to be transported by IFT particles (33), yet the purified BBSome does not contain IFT components. Another factor that may limit our detection of endogenous protein interactions is that the BBSome may only interact with hedgehog pathway components inside cilia, and only a portion of these proteins (both the BBSome and hedgehog pathway components) actually localize to cilia. Elevation of protein concentrations inside cells by overexpressing them will increase the chance to detect this type of interaction. That Smo co-localizes with BBSome particles inside the cilium (Supplementary Material, Fig. S2) indicates that they may interact in vivo.

The phenotypes of Bbs7 and Ift88orpk double mutants resemble those of complete knockout of IFT genes, indicating that they lose responsiveness to Shh ligand. Even though single homozygous mutants of either gene have diminished Shh responsiveness, single mutant mice survive to adulthood, in stark contrast to the double mutants. Creation of double mutants is an effective approach to evaluate the biological meaning of small effects like we observe for Shh pathway activation when BBS genes are deleted. The delayed development of the limb in the double-mutant embryos, together with the fact that the double mutants do not survive beyond e12.5, precludes the determination of the exact nature of digit development in the double mutants. To further support that double mutants might develop polydactyly, MEF cells from double mutants fail to form cilia (manuscript in preparation), unlike in any single mutants. Future deletion of BBS genes in the limb using Prx1-cre, which is expressed in the limb mesenchymal cells, along with crosses to Ift88orpk mice, will provide a definitive answer to this question.

MATERIALS AND METHODS

Antibodies and reagents

The hypomorphic Ift88 mouse, Oak Ridge Polycystic Kidney (orpk mouse), was kindly provided by Dr Gregory Pazour (University of Massachusetts Medical School, Worcester). SAG was purchased from Calbiochem (Gibbstown, NJ, USA). Rabbit anti-Smo antibody was from Abcam (Cambridge, MA, USA), anti-acetylated tubulin was purchased from Sigma (St. Louis, MO, USA), rabbit anti-Su(fu) and goat anti-IFT57 antibodies were purchased from Santa Cruz Biotechnology (Cambridge, MA, USA)

In vivo experiments: Human Molecular Genetics, 2012, Vol. 21, No. 9
Biotecnology (Santa Cruz, CA, USA). Rabbit anti-IFT57, IFT88, IFT20 and IFT81 were purchased from Proteintech (Chicago, IL, USA). Anti-Gli2 antibody is a gift from Dr Jonathan T. Eggenschwiler (Princeton University, Princeton, NJ, USA), anti-Patched 1 antibody is a gift from Dr Rajat Rohatgi (Stanford University, Stanford, CA, USA). Alexa 488-conjugated and Alexa 568-conjugated secondary antibodies were purchased from Invitrogen (Carlsbad, CA, USA).

**Generation of MEF cells**

WT and mutant (Bbs7−/−, Bbs2−/−, Bbs4−/− and Bbs1M390R/M390R knockout) primary MEFs were generated from embryonic day 12.5 embryos and cultured in Dulbecco’s modified Eagle medium with 10% fetal bovine serum and penicillin/streptomycin. To induce cilia formation, MEF cells were grown to day 12.5 embryos and cultured in Dulbecco’s modified Eagle medium with 10% fetal bovine serum and penicillin/streptomycin. MEF cells were lysed with 0.2% Triton X-100 in room temperature for 15 min. Cells were washed 3× with PBS, 1% Triton X-100 and protease inhibitor—Roche, Indianapolis, IN, USA) and spun at 14 000 rpm for 15 min at 4°C. The supernatants were cleared by incubation with protein G beads (Pierce, Rockford, IL, USA). Cleared lysates were incubated with antibodies against corresponding tags for 4 h. Protein G beads were then added and incubated for another 4 h. The beads were washed four times with lysis buffer and the interactions were detected by western blotting.

**Immunoprecipitation**

Differentially tagged human BBS genes (BBS1, BBS2, BBS4, BBS5, BBS7, BBS8 and BBS9) were co-transfected into 293T cells. Forty-eight hours after transfection, the cells were lysed in lysis buffer (1× phosphate buffered saline (PBS), 1% Triton X-100 and protease inhibitor—Roche, Indianapolis, IN, USA) and spun at 14 000 rpm for 15 min at 4°C. The supernatants were cleared by incubation with protein G beads (Pierce, Rockford, IL, USA). Cleared lysates were incubated with antibodies against corresponding tags for 4 h. Protein G beads were then added and incubated for another 4 h. The beads were washed four times with lysis buffer and the interactions were detected by western blotting.

**Immunofluorescence microscopy**

Cells were fixed in 4% paraformaldehyde in PBS and permeabilized with 0.2% Triton X-100 in room temperature for 7 min. Cells were washed 3× with PBS and blocked with blocking buffer (1% bovine serum albumin in PBS). Primary antibodies were diluted in blocking buffer and incubated at room temperature for 1 h. Cells were washed 3× with PBS, blocked with blocking buffer, then incubated with Alexa 488- or Alexa 568-labeled secondary antibodies (Invitrogen) for 45 min at room temperature. Nuclei were stained with DAPI (Sigma). The intensity of staining inside the cilia was measured using ImageJ.

**Quantitative RT–PCR**

RNA was isolated from DMSO- or SAG-treated MEF cells using TRIzol reagent (Invitrogen). cDNA was prepared from 1 μg of total RNA using SuperScript III reverse transcriptase (Invitrogen). Quantitative PCR was performed with SYBR Green Supermix (Bio-Rad) and Mx3000P qPCR System (Stratagene) with primers against mouse Gli1 and Patched 1. Mouse actin was used as an internal control. Primer sequences are available upon request.

**SUPPLEMENTARY MATERIAL**

Supplementary Material is available at HMG online.

**ACKNOWLEDGEMENTS**

The authors thank Dr Gregory Pazour (University of Massachusetts Medical School, Worcester) for providing Ift88sorpk mice, Dr Jonathan T. Eggenschwiler (Princeton University, Princeton) for anti-Gli2 antibody, Dr Rajat Rohatgi (Stanford University, Stanford) for anti-Patched 1 antibody. Dr Pao-Tien Chuang (University of California, San Francisco) for Flag-tagged Gli2 and Gli3 vectors.

**Conflict of Interest statement.** V.C.S. and E.M.S. are investigators of the Howard Hughes Medical Institute.

**FUNDING**

This work was supported by National Institute of Health grants [R01EY110298 and R01EY017168 (to V.C.S. and E.M.S.)]. Funding to pay the Open Access publication charges for this article was provided by Howard Hughes Medical Institute.

**REFERENCES**

1. Badano, J.L., Ansley, S.J., Leitch, C.C., Lewis, R.A., Lupski, J.R. and Katsanis, N. (2003) Identification of a novel Bardet–Biedl syndrome protein, BBS7, that shares structural features with BBS1 and BBS2. *Am. J. Hum. Genet.*, 72, 650–658.
2. Chiang, A.P., Beck, J.S., Yen, H.J., Tayeh, M.K., Scheetz, T.E., Swiderski, R.E., Nishimura, D.Y., Braun, T.A., Kim, K.Y., Huang, J. et al. (2006) Homozygosity mapping with SNP arrays identifies TRIM32, an E3 ubiquitin ligase, as a Bardet-Biedl syndrome gene (BBS11). *Proc. Natl Acad. Sci. USA*, 103, 6287–6292.
3. Chiang, A.P., Nishimura, D., Searby, C., Elbedour, K., Carmi, R., Ferguson, A.L., Secrist, J., Braun, T., Casavant, T., Stone, E.M. et al. (2004) Comparative genomic analysis identifies an ADP-ribosylation factor-like gene as the cause of Bardet–Biedl syndrome (BBS3). *Am. J. Hum. Genet.*, 75, 475–484.
4. Fan, Y., Esmail, M.A., Ansley, S.J., Blacque, O.E., Boroevich, K., Ross, A.J., Moore, S.J., Badano, J.L., May-Simera, H., Compton, D.S. et al. (2004) Mutations in a member of the Ras superfamily of small GTP-binding proteins causes Bardet–Biedl syndrome. *Nat. Genet.*, 36, 989–993.
5. Leitch, C.C., Zaghloul, N.A., Davis, E.E., Stoeztel, C., Diaz-Font, A., Rix, S., Alfadhel, M., Lewis, R.A., Eyaid, W., Banin, E. et al. (2008) Hypomorphic mutations in syndromic encephalocoele genes are associated with Bardet–Biedl syndrome. *Nat. Genet.*, 40, 443–448.
6. Li, J.B., Gerdes, J.M., Haycraft, C.J., Fan, Y., Tesловich, T.M., May-Simera, H., Li, H., Blacque, O.E., Li, L., Leitch, C.C. et al. (2004) Comparative genomics identifies a flagellar and basal body proteome that includes the BBS5 human disease gene. *Cell*, 117, 541–552.
7. Mykytyn, K., Braun, T., Carmi, R., Haider, N.B., Searby, C.C., Shastri, M., Beck, G., Wright, A.F., Iannaccone, A., Elbedour, K. et al. (2001) Identification of the gene that, when mutated, causes the human obesity syndrome BBS4. *Nat. Genet.*, 28, 188–191.
8. Mykytyn, K., Nishimura, D.Y., Searby, C.C., Shastri, M., Yen, H.J., Beck, J.S., Braun, T., Streb, L.M., Cornier, A.S., Cox, G.F. et al. (2002) Identification of the gene (BBS1) most commonly involved in Bardet–Biedl syndrome, a complex human obesity syndrome. *Nat. Genet.*, 31, 435–438.
9. Nishimura, D.Y., Searby, C.C., Carmi, R., Elbedour, K., Van Maldergem, L., Fulton, A.B., Lam, B.L., Powell, B.R., Swiderski, R.E., Bugge, K.E. et al. (2001) Positional cloning of a novel gene on chromosome 16q causing Bardet–Biedl syndrome (BBS2). *Hum. Mol. Genet.*, 10, 865–874.

**FUNDING**

This work was supported by National Institute of Health grants [R01EY110298 and R01EY017168 (to V.C.S. and E.M.S.)]. Funding to pay the Open Access publication charges for this article was provided by Howard Hughes Medical Institute.
21. Bai, C.B., Stephen, D. and Joyner, A.L. (2004) All mouse ventral spinal
19. Mykytyn, K., Mullins, R.F., Andrews, M., Chiang, A.P., Swiderski, R.E.,
14. Nachury, M.V., Loktev, A.V., Zhang, Q., Westlake, C.J., Peranen, J.,
16. Berbari, N.F., Lewis, J.S., Bishop, G.A., Askwith, C.C. and Mykytyn, K.
17. Davis, R.E., Swiderski, R.E., Rahmouni, K., Nishimura, D.Y., Mullins,
15. Berbari, N.F., Johnson, A.D., Lewis, J.S., Askwith, C.C. and Mykytyn, K.
13. Kim, S.K., Shindo, A., Park, T.J., Oh, E.C., Ghosh, S., Gray, R.S., Lewis,
11. Stoetzel, C., Laurier, V., Davis, E.E., Muller, J., Rix, S., Badano, J.L.,
25. Rohatgi, R., Milenkovic, L., Corcoran, R.B. and Scott, M.P. (2009)
22. Corbit, K.C., Shyer, A.E., Dowdle, W.E., Gaulden, J., Singla, V., Chen,
1952
10. Nishimura, D.Y., Swiderski, R.E., Searby, C.C., Berg, E.M., Ferguson,
A.L., Hennekam, R., Merin, S., Weleber, R.G., Biesescker, L.G., Stone,
E.M. et al. (2005) Comparative genomics and gene expression analysis
identifies BBS9, a new Bardet–Biedl syndrome gene. Am. J. Hum.
Genet., 77, 1021–1033.
12. Stoetzel, C., Laurier, V., Davis, E.E., Muller, J., Rix, S., Badano, J.L.,
Leitch, C.C., Salem, N., Choquy, E., Corbani, S. et al. (2006) BBS10 encodes
a vertebrate-specific chaperonin-like protein and is a major BBS locus. Nat.
Genet., 38, 521–524.
10. Nishimura, D.Y., Swiderski, R.E., Searby, C.C., Berg, E.M., Ferguson,
A.L., Hennekam, R., Merin, S., Weleber, R.G., Biesescker, L.G., Stone,
E.M. et al. (2005) Comparative genomics and gene expression analysis
identifies BBS9, a new Bardet–Biedl syndrome gene. Am. J. Hum.
Genet., 77, 1021–1033.
12. Stoetzel, C., Laurier, V., Davis, E.E., Muller, J., Rix, S., Badano, J.L.,
Leitch, C.C., Salem, N., Choquy, E., Corbani, S. et al. (2006) BBS10 encodes
a vertebrate-specific chaperonin-like protein and is a major BBS locus. Nat.
Genet., 38, 521–524.
10. Nishimura, D.Y., Swiderski, R.E., Searby, C.C., Berg, E.M., Ferguson,
A.L., Hennekam, R., Merin, S., Weleber, R.G., Biesescker, L.G., Stone,
E.M. et al. (2005) Comparative genomics and gene expression analysis
identifies BBS9, a new Bardet–Biedl syndrome gene. Am. J. Hum.
Genet., 77, 1021–1033.
12. Stoetzel, C., Laurier, V., Davis, E.E., Muller, J., Rix, S., Badano, J.L.,
Leitch, C.C., Salem, N., Choquy, E., Corbani, S. et al. (2006) BBS10 encodes
a vertebrate-specific chaperonin-like protein and is a major BBS locus. Nat.
Genet., 38, 521–524.
10. Nishimura, D.Y., Swiderski, R.E., Searby, C.C., Berg, E.M., Ferguson,
A.L., Hennekam, R., Merin, S., Weleber, R.G., Biesescker, L.G., Stone,
E.M. et al. (2005) Comparative genomics and gene expression analysis
identifies BBS9, a new Bardet–Biedl syndrome gene. Am. J. Hum.
Genet., 77, 1021–1033.
12. Stoetzel, C., Laurier, V., Davis, E.E., Muller, J., Rix, S., Badano, J.L.,
Leitch, C.C., Salem, N., Choquy, E., Corbani, S. et al. (2006) BBS10 encodes
a vertebrate-specific chaperonin-like protein and is a major BBS locus. Nat.
Genet., 38, 521–524.
10. Nishimura, D.Y., Swiderski, R.E., Searby, C.C., Berg, E.M., Ferguson,
A.L., Hennekam, R., Merin, S., Weleber, R.G., Biesescker, L.G., Stone,
E.M. et al. (2005) Comparative genomics and gene expression analysis
identifies BBS9, a new Bardet–Biedl syndrome gene. Am. J. Hum.
Genet., 77, 1021–1033.
12. Stoetzel, C., Laurier, V., Davis, E.E., Muller, J., Rix, S., Badano, J.L.,
Leitch, C.C., Salem, N., Choquy, E., Corbani, S. et al. (2006) BBS10 encodes
a vertebrate-specific chaperonin-like protein and is a major BBS locus. Nat.
Genet., 38, 521–524.
10. Nishimura, D.Y., Swiderski, R.E., Searby, C.C., Berg, E.M., Ferguson,
A.L., Hennekam, R., Merin, S., Weleber, R.G., Biesescker, L.G., Stone,
E.M. et al. (2005) Comparative genomics and gene expression analysis
identifies BBS9, a new Bardet–Biedl syndrome gene. Am. J. Hum.
Genet., 77, 1021–1033.
12. Stoetzel, C., Laurier, V., Davis, E.E., Muller, J., Rix, S., Badano, J.L.,
Leitch, C.C., Salem, N., Choquy, E., Corbani, S. et al. (2006) BBS10 encodes
a vertebrate-specific chaperonin-like protein and is a major BBS locus. Nat.
Genet., 38, 521–524.
10. Nishimura, D.Y., Swiderski, R.E., Searby, C.C., Berg, E.M., Ferguson,
A.L., Hennekam, R., Merin, S., Weleber, R.G., Biesescker, L.G., Stone,
E.M. et al. (2005) Comparative genomics and gene expression analysis
identifies BBS9, a new Bardet–Biedl syndrome gene. Am. J. Hum.
Genet., 77, 1021–1033.
12. Stoetzel, C., Laurier, V., Davis, E.E., Muller, J., Rix, S., Badano, J.L.,
Leitch, C.C., Salem, N., Choquy, E., Corbani, S. et al. (2006) BBS10 encodes
a vertebrate-specific chaperonin-like protein and is a major BBS locus. Nat.
Genet., 38, 521–524.
10. Nishimura, D.Y., Swiderski, R.E., Searby, C.C., Berg, E.M., Ferguson,
A.L., Hennekam, R., Merin, S., Weleber, R.G., Biesescker, L.G., Stone,
E.M. et al. (2005) Comparative genomics and gene expression analysis
identifies BBS9, a new Bardet–Biedl syndrome gene. Am. J. Hum.
Genet., 77, 1021–1033.
12. Stoetzel, C., Laurier, V., Davis, E.E., Muller, J., Rix, S., Badano, J.L.,
Leitch, C.C., Salem, N., Choquy, E., Corbani, S. et al. (2006) BBS10 encodes
a vertebrate-specific chaperonin-like protein and is a major BBS locus. Nat.
Genet., 38, 521–524.
10. Nishimura, D.Y., Swiderski, R.E., Searby, C.C., Berg, E.M., Ferguson,
A.L., Hennekam, R., Merin, S., Weleber, R.G., Biesescker, L.G., Stone,
E.M. et al. (2005) Comparative genomics and gene expression analysis
identifies BBS9, a new Bardet–Biedl syndrome gene. Am. J. Hum.
Genet., 77, 1021–1033.
12. Stoetzel, C., Laurier, V., Davis, E.E., Muller, J., Rix, S., Badano, J.L.,
Leitch, C.C., Salem, N., Choquy, E., Corbani, S. et al. (2006) BBS10 encodes
a vertebrate-specific chaperonin-like protein and is a major BBS locus. Nat.
Genet., 38, 521–524.
47. Sugiyama, N., Tsukiyama, T., Yamaguchi, T.P. and Yokoyama, T. (2011) The canonical Wnt signaling pathway is not involved in renal cyst development in the kidneys of inv mutant mice. *Kidney Int.*, 79, 957–965.
48. Lancaster, M.A., Gopal, D.J., Kim, J., Saleem, S.N., Silhavy, J.L., Louie, C.M., Thacker, B.E., Williams, Y., Zaki, M.S. and Gleeson, J.G. (2011) Defective Wnt-dependent cerebellar midline fusion in a mouse model of Joubert syndrome. *Nat. Med.*, 17, 726–731.
49. Lancaster, M.A., Louie, C.M., Silhavy, J.L., Sintasath, L., Decambre, M., Nigam, S.K., Willert, K. and Gleeson, J.G. (2009) Impaired Wnt-beta-catenin signaling disrupts adult renal homeostasis and leads to cystic kidney ciliopathy. *Nat. Med.*, 15, 1046–1054.
50. McDermott, K.M., Liu, B.Y., Tlsty, T.D. and Pazour, G.J. (2010) Primary cilia regulate branching morphogenesis during mammary gland development. *Curr. Biol.*, 20, 731–737.
51. Simons, M., Gloy, J., Ganner, A., Bulkerkote, A., Bashkurov, M., Kronig, C., Schermer, B., Benzing, T., Cabello, O.A., Jenny, A. et al. (2005) Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. *Nat. Genet.*, 37, 537–543.
52. Ocbina, P.J., Eggenschwiler, J.T., Moskowitz, I. and Anderson, K.V. (2011) Complex interactions between genes controlling trafficking in primary cilia. *Nat. Genet.*, 43, 547–553.
53. Blacque, O.E., Reardon, M.J., Li, C., McCarthy, J., Mahjoub, M.R., Ansley, S.J., Badano, J.L., Mah, A.K., Beales, P.L., Davidson, W.S. et al. (2004) Loss of *C. elegans* BBS-7 and BBS-8 protein function results in cilia defects and compromised intraflagellar transport. *Genes Dev.*, 18, 1630–1642.
54. Chen, M.H., Wilson, C.W., Li, Y.J., Law, K.K., Lu, C.S., Gacayan, R., Zhang, X., Hui, C.C. and Chuang, P.T. (2009) Cilium-independent regulation of Gli protein function by Sufu in hedgehog signaling is evolutionarily conserved. *Genes Dev.*, 23, 1910–1928.
55. Hunke, E.W., Dorn, K.V., Milenkovic, L., Scott, M.P. and Rohatgi, R. (2010) The output of hedgehog signaling is controlled by the dynamic association between suppressor of fused and the Gli proteins. *Genes Dev.*, 24, 670–682.
56. Tukachinsky, H., Lopez, L.V. and Salic, A. (2010) A mechanism for vertebrate hedgehog signaling: recruitment to cilia and dissociation of SuFu–Gli protein complexes. *J. Cell Biol.*, 191, 415–428.
57. Lum, L., Zhang, C., Oh, S., Mann, R.K., von Kessler, D.P., Taipale, J., Weis-Garcia, F., Gong, R., Wang, B. and Beachy, P.A. (2003) Hedgehog signal transduction via smoothed association with a cytoplasmic complex scaffolded by the atypical kinesin, Costal-2. *Mol. Cell.*, 12, 1261–1274.